Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 10, 2010. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in share interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific share transaction rather than a financial performance report.
Material Changes
The only material change disclosed is a reduction in shareholding by a connected person:
- Individual: Mr. M Dunoyer
- Transaction: Sale of 13,853 Ordinary shares
- Date: August 10, 2010
- Price: £11.72 per share
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly limited to the notification of the share sale in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the total remaining shareholding of Mr. M Dunoyer following this sale.
- Confirm the market price of GSK shares on August 10, 2010, to validate the transaction price of £11.72.
- Check for any other concurrent director transactions not included in this specific notification.